The updated COVID-19 shots that rolled out in fall 2023 reduced the risk of severe infection by 31% in adults over 65 and immunocompromised individuals, according to data published March 4 by ...

The U.S. Covid-19 Public Health Emergency declaration may have ended, but the virus remains. Now is the moment to leverage the successes and challenges of fostering innovative Covid therapeutics to ...

Influenza cases are rising sharply, heightening fears that a new strain will fuel a punishing flu season that is already outpacing last year’s. Photo: Brendan McDermid/Reuters If everyone you know ...

A recent study published in JAMA Network Open examined the efficacy of nirmatrelvir-ritonavir and molnupiravir in non-hospitalized patients with coronavirus disease 2019 (COVID-19) and type 2 diabetes ...

Viruses, like those that cause COVID-19 or HIV, are formidable opponents once they invade our bodies. Antiviral treatments strive to block a virus or halt its replication. However, viruses are dynamic ...

When it comes to COVID, people living in disadvantaged communities are hit with a triple whammy. First, they’re more likely to get infected, and when sick, are more likely to have serious disease.

The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic - an effective antiviral that has since successfully treated millions. But like many antivirals before it ...

FOR THE RECORD, WE WANT TO TALK NOW ABOUT ANTIVIRALS. IT’S SOMETHING MANY OF US HAVE QUESTIONS ABOUT WHEN ILLNESS STRIKES US OR OUR FAMILIES, OUR KRISTEN POWERS SPEAKS WITH INFECTIOUS DISEASE EXPERT ...